Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Meyyappan Somasundaram

Internal Medicine Independence, OH Medical Doctor

NPI 1831188168 CMS profile 264437

6701 Rockside Rd, Suite 100, Independence, OH 44131

Open in the dashboard

General payments

$8,215

352 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meyyappan Somasundaram of Independence, OH is reported in the CMS Open Payments database as having received $8,215 across 352 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,639 99
2024 General $1,717 69
2023 General $945 49
2022 General $1,034 54
2021 General $1,128 51
2020 General $391 20
2019 General $361 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meyyappan Somasundaram
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Meyyappan Somasundaram were reported at $2,639. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Meyyappan Somasundaram Internal Medicine median Middle half National median
2019 $361 $159 $48–$570 $163
2020 $391 $119 $33–$402 $114
2021 $1,128 $135 $37–$521 $132
2022 $1,034 $141 $42–$496 $149
2023 $945 $149 $45–$519 $160
2024 $1,717 $154 $47–$537 $164
2025 $2,639 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $908 22 payments
  2. AbbVie, Inc. $894 45 payments
  3. Vanda Pharmaceuticals Inc. $683 30 payments
  4. Novo Nordisk Inc $457 19 payments
  5. Amgen Inc. $456 18 payments
  6. Lilly USA, LLC $396 22 payments
  7. Xeris Pharmaceuticals, Inc. $288 8 payments
  8. Exact Sciences Corporation $281 14 payments
  9. Harmony Biosciences LLC $269 9 payments
  10. Abbott Laboratories $269 12 payments
  11. Other $3,315 153 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,071 348 payments
  2. Education $144 4 payments
Products named General payments · program years 2019–2025
  1. FANAPT $683 30 payments
  2. AIRSUPRA $462 8 payments
  3. UBRELVY $381 16 payments
  4. MOUNJARO $374 21 payments
  5. NURTEC ODT $364 14 payments
  6. LOKELMA $348 8 payments
  7. RYBELSUS $281 12 payments
  8. Otezla $268 12 payments
  9. VRAYLAR $253 14 payments
  10. REXULTI $250 12 payments
  11. Other $5,304 279 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 237 drugs

Part D claims

17,982

Median for Internal Medicine: 777

Drug cost

$1,206,451

Median for Internal Medicine: $73,373

Branded share of claims

21.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 741 $238,828
Xeljanz Xr Tofacitinib Citrate Brand 12 $73,998
Jardiance Empagliflozin Brand 76 $55,048
Trulicity Dulaglutide Brand 111 $45,881
Ozempic Semaglutide Brand 24 $45,587
Mounjaro Tirzepatide Brand 32 $45,444
Farxiga Dapagliflozin Propanediol Brand 73 $38,655
Xarelto Rivaroxaban Brand 59 $33,512
Vraylar Cariprazine Hcl Brand 21 $32,254
Entresto Sacubitril/Valsartan Brand 30 $26,894

The 10 drugs with the highest cost, of 237 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$141,107

Medicare's payments for the services billed

Medicare patients

328

Average age 74

Services billed

1,905

171 women, 157 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Heart failure 42%
Diabetes 40%
Ischemic heart disease 39%
Chronic kidney disease 39%
Depression 38%
Atrial fibrillation 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LOKELMA
  • AstraZeneca Pharmaceuticals LP $348
$348 40 —
FANAPT
  • Vanda Pharmaceuticals Inc. $231
$231 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $125
$125 — —
VRAYLAR
  • AbbVie, Inc. $106
$106 21 —
MOUNJARO
  • Lilly USA, LLC $60
$60 32 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

352 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record